Member of the French affiliate Executive Committee since Oct 2013 (Amgen SAS - 550M€ / 350 HCs)Team of 3- Designed & implemented the new commercial organisation (created a new Cardiology BU / enlarged the Haematology line / partnered with HR & training team to ensure up-and-running new FF lines of 100+ SF positions / 20+RMLs)- Head of local New Product Development Lead teams (Cardiology, Inflam., Oncology) : Represented France at the Global Product team by providing input, insights into the local market environment to inform and develop differentiated product strategy- Defined the local Biosimilar strategy & structure- Defined & Implemented locally a new customer engagement model leveraging multichannel ( incl. change management and new capabilities development)

Head of Market Research / Business Planning / SFE /Training / Congress & Event / Sales Operations / Transparency Publication – team of 22 – budget of 3,5M €• Strategic Planning: performed the affiliate Long Range Planning and new products forecast, supported budget process (defined top line for all Bus) , produced Business Review for presentation to EU CEO , supported affiliate governance redesign & implementation ...• Social plan : supported the decision and the design of the new organisation, simulated the To-Be SF organisation, wrote part of legal documentations (economical rational, …)• Strategic thinking & recommendation: performed SF increasing business case, redesigned SF governance (RM role), supported product repositioning (Neulasta)• Licensing out: assessed locally potential EU partners (Prolia®)• Partnering with BUs: performed European monthly reporting, broadcasted performance figures trough the affiliate using new technology, solidified CI process and outputs, defined and performed MR plan• Transversal project: Prolia® supply chain, EPO integration within DRG, price cut impact assessment, new product price negotiation, demand forecast (best affiliate 6 years in a raw), .... • Operation Excellence: defined new solution platforms for performance analysis, sales incentive plan, sunshine act like publication and sales activities

Teal of 8

Team of 4

Team of 3• Business development (part of the core team with Stallergenes CEO and COO): assessed the potential partners for an alliance in North America, negotiated the license, run due diligence, coordinated M&A activities with Rothschild & HSBC• Company business cycle: designed and presented the10 years Business Plan (P&L) to shareholders (Wendel- Investment), implemented affiliates’ strategic 3-year-plan and marketing plan, implemented monthly performance reporting, developed competitor analysis (development plan & investments)

Senior Consultant• Carve-out management: - Created of a 50 M€ funded biotech newCo - Business Plan / Negotiation with investors - Designed and implement business infrastructure • Clinical efficiency: - Electronic clinical data management- Portfolio screening- Process design re-engineering • Supply chain:- Post merging organisational impacts- ERP / Process design re-engineering - Category management• Marketing effectiveness :- Marketing processes re-engineering